Moderna

Promosome LLC Sues Moderna, Pfizer, and BioNTech for COVID-19 Vaccine Patent Infringement

Retrieved on: 
Wednesday, June 7, 2023
Vaccine, 1836 U.S. Patent Office fire, BioNTech, Patent, CAB, JES, COVID-19, Messenger, Moderna, SAN, Scripps Research, Pharmaceutical industry, Pfizer

SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.

Key Points: 
  • SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.
  • The suits allege that the mRNA-based COVID-19 vaccines produced by these companies violate patented technology owned by Promosome.
  • While Moderna did not license the '179 Patent, mRNA sequence reverse engineering shows that Moderna took the patented technology for its vaccine, Spikevax®.
  • The second lawsuit, against Pfizer and BioNTech, alleges that Pfizer and BioNTech's joint COVID-19 vaccine Comirnaty® willfully infringes the '179 Patent.

COVID-19 vaccination: No serious side effects in young children

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, HealthPartners, Seizure, Denver Health Medical Center, Partnership, Vaccination, Coronavirus, Stroke, COVID-19, Myocarditis, Kaiser Permanente, Doctor of Philosophy, Parent, Messenger, CDC, Vaccine Safety Datalink, Marshfield Clinic, MD, Division, Risk, Korea Disease Control and Prevention Agency, Kaiser Permanente Arena, MPH, Immunization, Roger Hawkins (drummer), Family, Encephalitis, Pfizer, Pericarditis, Pharmaceutical industry, Pediatrics, Moderna, Research

OAKLAND, Calif., June 6, 2023 /PRNewswire/ -- A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects. The study, published June 6 in Pediatrics, was led by the Kaiser Permanente Division of Research in partnership with the Centers for Disease Control and Prevention.

Key Points: 
  • OAKLAND, Calif., June 6, 2023 /PRNewswire/ -- A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects.
  • The Pediatrics study marks the first analysis looking for serious side effects from the mRNA vaccines in young children.
  • The study examined medical records for 23 serious potential side effects, including outcomes such as blood clots, seizures, stroke, and brain inflammation.
  • "Parents can protect their young children from COVID-19 in the same way they vaccinate their children to protect from other serious childhood diseases."

ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

Retrieved on: 
Wednesday, May 24, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, SoftBank Vision Fund, RGN, California Institute for Regenerative Medicine, Partnership, Good manufacturing practice, IPSC, Itochu, Gene editing, Life, Venture round, Mountaineering, California Institute for Telecommunications and Information Technology, RNA, Cell, Regenerative medicine, Emerson Collective, Acquisition, CGMP, Moderna, Novo Nordisk, Growth, Ecosystem, Therapy, Disease, Vaccine, Fine chemical, Citadel

In connection with the financing, Khalil Barrage, Managing Director of The Invus Group, was appointed to ElevateBio’s Board of Directors.

Key Points: 
  • In connection with the financing, Khalil Barrage, Managing Director of The Invus Group, was appointed to ElevateBio’s Board of Directors.
  • “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company.
  • In connection with Novo Nordisk’s investment in the Series D financing, ElevateBio’s integrated subsidiary Life Edit Therapeutics also announced a multi-target collaboration with Novo Nordisk to discover and develop base editing therapies.
  • The company has also increased BaseCamp manufacturing and process development capabilities to support a growing number of cell and gene therapy innovators.

ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine

Retrieved on: 
Tuesday, May 23, 2023
Biotechnology, Genetics, Health, Boston Consulting Group, Tissue, Therapy, Senior, Arena Pharmaceuticals, Renegade, Bristol Myers Squibb, Cell, RNA, Partner, Merck, Johnson & Johnson, Shirin David, LNP, MPM, Disease, J. P. Morgan, Vaccine, Moderna, Alnylam Pharmaceuticals

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.
  • ReNAgade aims to address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body, substantially expanding the potential addressable disease market.
  • The Company has an established Joint Venture with Orna Therapeutics Inc., combining ReNAgade’s delivery platform with Orna’s circular RNA technology.
  • “By innovating on delivery technology and bringing an array of genomic medicine tools under one roof, ReNAgade is poised to deliver RNA to organs and tissues not previously accessible.

SEEDS - Access Changes Everything to Host Panel Discussion on Professional Networks for Marginalized Youth

Retrieved on: 
Tuesday, May 16, 2023
HR, SEEDS, Inclusion, Moderna

NEWARK, N.J., May 16, 2023 /PRNewswire/ -- SEEDS - Access Changes Everything is proud to announce the next installment of its Academic and Student Affairs Panel Discussion series.

Key Points: 
  • NEWARK, N.J., May 16, 2023 /PRNewswire/ -- SEEDS - Access Changes Everything is proud to announce the next installment of its Academic and Student Affairs Panel Discussion series.
  • The upcoming panel will focus on the importance of professional networks in building access to and through careers for young people from marginalized backgrounds.
  • "We are thrilled to host this important conversation on the role of professional networks in building access for marginalized youth," said SEEDS - Access Changes Everything CEO & President, John F. Castano.
  • "Access to professional networks is particularly critical for young people from low-income households to succeed in their careers, and we hope that this panel discussion will provide valuable insights and strategies for building these networks."

Alcatraz AI Appoints Moderna’s Dean Geribo to Advisory Board

Retrieved on: 
Tuesday, May 16, 2023
Intelligence, Ground based operational surveillance system, Chief security officer, Organization, Friction, Machine learning, Corporation, AI, Dairy, Rock, Moderna

CUPERTINO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Alcatraz AI , a global leader in autonomous access control solutions, today announced the appointment of Dean Geribo, Vice President, Corporate Security at Moderna, to its advisory board.

Key Points: 
  • CUPERTINO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Alcatraz AI , a global leader in autonomous access control solutions, today announced the appointment of Dean Geribo, Vice President, Corporate Security at Moderna, to its advisory board.
  • "Dean is going to be a tremendous asset to the Alcatraz AI team," said Tina D'Agostin, CEO of Alcatraz AI.
  • Geribo has decades of experience in leadership and corporate security, and also serves as an advisory board member for Base Operations, the Board of Executive Protection Professionals, HiveWatch, and RaySecur.
  • Moderna is currently in pilot with the Rock , Alcatraz AI’s flagship device that combines facial biometrics, AI, and machine learning for greater security and less friction.

Global mRNA Synthesis Raw Materials Market Report 2023: Increasing Funding For mRNA Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 12, 2023
Biotechnology, Pharmaceutical, Health, Vaccine, Failure, Therapy, Half-life, National Institute of Allergy and Infectious Diseases, COVID-19, Research, Moderna, Infection, RNA, USD, AstraZeneca, Acuitas Therapeutics, Messenger, Novartis, Genome, Developed country, Application, Investment, Alexion, Growth, NIAID, Sanofi Pasteur, Pharmaceutical industry, Fine chemical, Nucleotide, LNP, Pfizer

The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030.

Key Points: 
  • The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030.
  • The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research.
  • In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.
  • The COVID-19 pandemic has increased the demand for mRNA synthesis raw materials for developing an efficient vaccine to battle infectious diseases.

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
DNA, Partnership, University, Liver disease, Generation, Harvard University School of Mining and Practical Geology, G&A, Research, Liver, R, LNP, Haemophilia, Virginia School for Girls, D, Pharmaceutical industry, Vaccine, Moderna

CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2023 financial results.

Key Points: 
  • First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023
    CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co .
  • (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2023 financial results.
  • R&D Expenses: Research and development (R&D) expenses were $22.0 million for the quarter ended March 31, 2023, compared to $25.6 million for the quarter ended March 31, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $12.9 million for the quarter ended March 31, 2023, compared to $9.8 million for the quarter ended March 31, 2022.

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 9, 2023
Workforce, Amgen, Epithelial cell adhesion molecule, Doctor of Philosophy, Regeneron Pharmaceuticals, CD3, Therapeutic index, Exelixis, Cancer, Lead, EST, Bristol Myers Squibb, Research, Inflammation, PST, Genentech, Trial of the century, Acquisition, Patent, Patient, AbbVie, Investment, EGFR, SAN, CD71, Webcast, Interferon, ADC, BMS, Cytokine, Spacecraft, Therapy, Bi-specific T-cell engager, Tumor microenvironment, Safety, TCB, Pharmaceutical industry, Astellas Pharma, Moderna, IND

“As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody® therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.

Key Points: 
  • “As we entered 2023, CytomX continued the advancement of our diversified portfolio of innovative Probody® therapeutic candidates for the treatment of cancer while ensuring disciplined resource allocation,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
  • CX-904 is partnered with Amgen and is being evaluated by CytomX in an ongoing Phase 1 study in patients with advanced solid tumors.
  • CytomX and Astellas are collaborating on additional conditionally activated TCB programs, and CytomX is eligible to receive future preclinical, clinical, and commercial milestones.
  • ET (2 p.m. PT) to discuss the financial results and provide a business update.

Top Cybersecurity Leaders Join Rubrik CISO Advisory Board Chaired by Chris Krebs

Retrieved on: 
Wednesday, April 5, 2023
Advisory board, Nokia, Senior, CISO, U.S. Department of Defense Strategy for Operating in Cyberspace, Policy, SVP, Wayfair, White House, Face, PALO, Hughes, RSA Conference, DGA, Research, Public sector, Organization, Administration, Commander, Albertsons, CRM, Growth, Entrepreneurship, Woman, Conference, Private sector, White, Directorate, United States Department of the Army, Schneider Electric, FBI, Aggarwal, CPSO, Johnson & Johnson, Booking.com, Financial services, Senior advisor, CISA, Security, Comprehension, Here Technologies, Ciso, Computer security, Arms industry, Management, Cryptocurrency, Moderna, Defense, Rubrik

In the spirit of the new industry framework, Rubrik , the Zero Trust Data Security™ Company, today announced the members of its CISO Advisory Board.

Key Points: 
  • In the spirit of the new industry framework, Rubrik , the Zero Trust Data Security™ Company, today announced the members of its CISO Advisory Board.
  • Rubrik’s CISO Advisory Board is chaired by Chris Krebs, the first Director of the U.S. Cybersecurity and Infrastructure Security Agency (CISA) and founding partner of the Krebs Stamos Group.
  • “Our CISO Advisory Board brings together some of the brightest minds in cybersecurity, with real world experience to help us advance data security innovation.
  • New CISO Board Members include:
    Aaron Hughes, Senior Vice President and CISO, Albertsons
    Aaron Hughes is the Senior Vice President and CISO at Albertsons Companies.